Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers.
News
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the "Merger"), wher
Read more
Report
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer
Read more
Report
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
Read more
Report
BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA in Patients With Advanced NSCLC
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the...
Read more
Report